What is Aspira Women's Health Inc. (AWH)?

Aspira Women's Health Inc. (AWH) is a stock in the Healthcare sector, Medical - Diagnostics & Research industry. View full analysis on Stocks360.

What is the current price of AWH?

The current price of AWH is $0.08. Prices are updated in real time on Stocks360.

What is AWH's price-to-earnings (PE) ratio?

AWH's trailing twelve-month PE ratio is -0.34, based on current price and earnings per share data available on Stocks360.

What is AWH's market capitalization?

AWH's market capitalization is $2,458,610.00, placing it in the small-cap tier.

Aspira Women's Health Inc. (AWH)

Stock analysis · NASDAQ · Healthcare · Medical - Diagnostics & Research

$0.08

Market Cap

$2.46M

PE (TTM)

-0.34

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

2.01

Day Range

$0.08 – $0.08

52-wk Range

$0.08 – $3.63

Avg Volume

N/A

Volume

443.52K

Aspira Women's Health Inc. (AWH) is a publicly traded company in the Healthcare sector. Latest price: $0.08. Market cap $2.46M. Trailing PE -0.34. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2026-01-30 · $0.08 2026-02-10 · $0.08 (+0.00%)

Earnings

Most Recent

May 13, 2025

EPS $-8.58 vs est. $-0.15

Missed by $8.43

Proprietary Signals

Signal snapshot temporarily unavailable.

About Aspira Women's Health Inc.

Aspira Women's Health Inc., alongside its subsidiaries, specializes in the development and commercialization of diagnostic tools for gynecologic diseases across the United States. Their product portfolio includes tests such as OVA1, OVERA, and OVA1plus, designed to evaluate the risk of ovarian malignancy in women presenting with adnexal masses. Additionally, they provide ASPiRA GenetiX, a genetic screening option for assessing individual susceptibility to gynecologic cancers. The company operates Aspira Synergy, a cloud-based platform enabling decentralized access to protein biomarker and hereditary genetic testing. Furthermore, Aspira owns and manages ASPiRA LABS, a specialized laboratory dedicated to applying advanced biomarker technologies for the management of gynecologic cancers and related conditions. Its innovation pipeline features upcoming products like OVAWatch, EndoCheck, and OVAInherit. Aspira serves a diverse clientele, including individual physicians, physician office laboratories, and both national and regional laboratory networks. The company actively collaborates with several institutions, holding a research agreement with Baylor Genetics and another with Harvard…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.34×
P/S (TTM)	0.29×
P/B	-0.50×
P/FCF (TTM)	-0.52×
EV / EBITDA	1.63×
EV / Sales	0.53×
Earnings Yield	-275.74%
Free Cash Flow Yield	-192.30%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$4.54M
Revenue (TTM)	$8.55M
Net Income (TTM)	-$6.78M
Free Cash Flow (TTM)	-$5.17M
Net Debt	$2.08M
Working Capital	-$2.54M
Gross Margin	58.78%
Operating Margin	-80.75%
Net Margin	-117.07%
Return on Equity	161.77%
Return on Invested Capital	1543.85%